

1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. *Eur J Cancer* 2002;38(18):2435-45.
2. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1992;10(5):718-26.
3. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. *Obstetrics and gynecology* 2006;107(6):1399-410.
4. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. *National Cancer Institute monograph* 1975;42:101-4.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol* 2002;20(5):1248-59.
6. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. *American journal of obstetrics and gynecology* 1994;170(4):974-9; discussion 9-80.
7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. *Obstetrics and gynecology* 1983;61(4):413-20.

8. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. *Obstetrics and gynecology* 2006;107(1):77-85.
9. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. *Lancet* 1984;2(8403):594-600.
10. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *J Clin Oncol* 1992;10(5):706-17.
11. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *The New England journal of medicine* 1996;334(1):1-6.
12. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. *J Clin Oncol* 2000;18(1):106-15.
13. Bookman MA. GOG 182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. In: 2006 ASCO Annual Meeting; 2006; Chicago, IL: *Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, Part 1; 2006. p. 18S (June 20 Supplement): 5002.*

14. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2003;83 Suppl 1:135-66.
15. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2003;21(17):3194-200.
16. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *The New England journal of medicine* 2006;354(1):34-43.
17. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. *Gynecologic oncology* 2000;78(3 Pt 1):269-74.
18. Eisenkop SM, Spirtos NM, Lin WC. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. *Gynecologic oncology* 2006;103(1):329-35.
19. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? *Gynecologic oncology* 2001;82(3):435-41.
20. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. *Gynecologic oncology* 2006;100(1):33-7.
21. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM. Ovarian cancer: patterns of surgical care across the United States. *Gynecologic oncology* 2006;103(2):383-90.

22. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. *Gynecologic oncology* 1992;47(2):203-9.
23. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. *Journal of the National Cancer Institute* 2006;98(3):172-80.
24. Eisenkop SM, Spirtos NM. The relative importance of surgical training and laboratory research in a gynecologic oncology fellowship. *Int J Gynecol Cancer* 2004;14(1):23-34.
25. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. *Gynecologic oncology* 2004;94(3):650-4.
26. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. *Gynecologic oncology* 1992;47(2):159-66.
27. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Peticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. *Gynecologic oncology* 2003;90(2):390-6.

28. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? *Gynecologic oncology* 2001;82(3):489-97.
29. Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. *Journal of cancer research and clinical oncology* 2002;128(3):153-60.
30. Brown DL, Zou KH, Tempany CM, et al. Primary versus secondary ovarian malignancy: imaging findings of adnexal masses in the Radiology Diagnostic Oncology Group Study. *Radiology* 2001;219(1):213-8.
31. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. *Radiology* 2000;215(3):761-7.
32. Coakley FV. Staging ovarian cancer: role of imaging. *Radiol Clin North Am.* 2002 May;40(3):609-36.
33. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. *Radiology* 2002;223(2):495-9.
34. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. *Gynecol Oncol.* 2005;96(2):301-6.
35. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. *Cancer.* 2004;101(2):346-52.

36. Bristow RE, Simpkins F, Pannu HK, Fishman EK, Montz FJ. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. *Gynecol Oncol.* 2002;85(1):196-200.
37. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. *Gynecol Oncol.* 2005;97(1):183-91.
38. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. *J Clin Oncol.* 2005;23(30):7445-53.
39. Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. *J Reprod Med.* 1996;41(3):140-2.
40. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. *Gynecol Oncol.* 2000;77(2):227-31.
41. Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. *Acta Obstet Gynecol Scand.* 2001;80(6):583-5.
42. Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? *Gynecol Oncol.* 2002;86(1):57-61.

43. Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, Bridges JE. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. *Int J Gynecol Cancer*. 2004;14(1):42-50.
44. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. *Cancer*. 2000;89(7):1532-40.
45. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. *Int J Gynecol Cancer*. 2003;13(2):120-4.
46. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. *Gynecol Oncol*. 1997;64(1):9-12.
47. Juretzka MM, Abu-Rustum NR, Sonoda Y, Downey RJ, Flores RM, Park BJ, Hensley ML, Barakat RR, Chi DS. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. *Gynecol Oncol*. 2007;104(3):670-4.
48. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. *Gynecol Oncol*. 1999;72(3):278-87.
49. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. *Gynecol Oncol*. 1999;72(1):93-9

50. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med.* 1995;332(10):629-34.
51. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. *N Engl J Med.* 2004;351(24):2489-97.
52. Everett EN, Heuser CC, Pastore LM, Anderson WA, Rice LW, Irvin WP, Taylor PT. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. *Am J Obstet Gynecol.* 2005;193(2):568-74.
53. Eisenkop SM, Spirtos NM, Friedman RL. Neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol.* 1999 Aug;74(2):311-2.
54. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. *Gynecol Oncol.* 2006;103(3):1070-6.
55. Barter JF and Barnes WA. Second -look laparotomy. In: Rubin S, Sutton G, eds. Ovarian Cancer. New York:McGraw-Hill, 1993:269-300.
56. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with

advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol.* 2003;21(13):2460-5.

57. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol.* 2001;19(4):1001-7.

58. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. *Am J Obstet Gynecol.* 2004;190(4):910-25.

59. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 5009.